Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung
Owen Proudfoot, Sandra Esparon, Choon-Kit Tang, Karen Laurie, Ian Barr, Geoffrey Pietersz
BMC INFECTIOUS DISEASES | BIOMED CENTRAL LTD | Published : 2015
BACKGROUND: H1N1 influenza viruses mutate rapidly, rendering vaccines developed in any given year relatively ineffective in subsequent years. Thus it is necessary to generate new vaccines every year, but this is time-consuming and resource-intensive. Should a highly virulent influenza strain capable of human-to-human transmission emerge, these factors will severely limit the number of people that can be effectively immunised against that strain in time to prevent a pandemic. An adjuvant and mode of administration capable of rendering ordinarily unprotective vaccine doses protective would thus be highly advantageous. METHODS: The carbohydrate mannan was conjugated to whole inactivated H1N1 in..View full abstract
Awarded by NHMRC 'Special Pandemic Influenza Grant'
Awarded by subsequent NHMRC 'Development Grant'
This study was supported by an NHMRC 'Special Pandemic Influenza Grant' (#365240), a subsequent NHMRC 'Development Grant' (#488420), and by the Victorian Operational Infrastructure Support Program.